Back to top
more

Biomea Fusion (BMEA)

(Delayed Data from NSDQ)

$5.77 USD

5.77
421,439

-0.33 (-5.41%)

Updated Aug 7, 2024 04:00 PM ET

After-Market: $5.78 +0.01 (0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for BMEA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Biomea Fusion, Inc. [BMEA]

Reports for Purchase

Showing records 1 - 20 ( 51 total )

Company: Biomea Fusion, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

06/25/2024

Company Report

Pages: 8

Overly Beat Up Ahead of Strong Projected Resurgence; Investment Case Right Now

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Biomea Fusion, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

06/25/2024

Company Report

Pages: 8

Overly Beat Up Ahead of Strong Projected Resurgence; Investment Case Right Now

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Biomea Fusion, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

06/07/2024

Company Report

Pages: 8

Headline Hit for Diabetes; Topline T2D Expansion Phase Data 4Q24; Target Reduced to $15

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Biomea Fusion, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

05/30/2024

Daily Note

Pages: 6

Patient Enrollment Wraps Up in COVALENT-111; Topline Data Anticipated in 4Q24

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Biomea Fusion, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

05/03/2024

Company Report

Pages: 11

1Q24 Results; BMF Trials Progressing as Planned; Shaping 219?s Registrational Path With Additional Diabetes Data in 2024

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Biomea Fusion, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

04/01/2024

Company Report

Pages: 11

Initial Proof of Concept Data Show BMF-219 Potential Also in T1D; Building a Case for Upcoming Phase 3 Studies

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Biomea Fusion, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

03/06/2024

Company Report

Pages: 12

200 mg Data Highlight Off-Treatment Sustained Efficacy in T2D; Expansion Phase Ongoing; Initial T1D Data Soon

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Biomea Fusion, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

02/12/2024

Industry Report

Pages: 25

Menin Inhibitors Carving Out a Niche in Leukemias: Rationale, Opportunities, and Candidates

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 75.00

Research Provided by a Third Party

Company: Biomea Fusion, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

01/31/2024

Daily Note

Pages: 114

2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: Biomea Fusion, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

01/30/2024

Daily Note

Pages: 115

2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: Biomea Fusion, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

01/10/2024

Company Report

Pages: 12

Covalent Inhibitors Unleashing Their Talents; T2D and T1D Data in 2024; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Biomea Fusion, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

01/09/2024

Company Report

Pages: 13

Phase 2 COVALENT-112 Up and Dosing T1D Patients; Data Anticipated in 2024; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 50.00

Research Provided by a Third Party

Company: Biomea Fusion, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

12/12/2023

Company Report

Pages: 13

ASH Underscores BMF-219?s Initial Antileukemic Efficacy; Phase 1 COVALENT-101 Progressing As Planned

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Biomea Fusion, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

12/11/2023

Company Report

Pages: 10

Higher Dose COVALENT-111 Results Indicate Enhanced Glycemic Control at Week 26; Additional Long-Term Data in 1Q24

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Biomea Fusion, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

12/08/2023

Company Report

Pages: 10

BMF-219 Completes 22-Week Off-Treatment Marathon; Continued Glycemic Control Keeps Drawing Our Attention

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Biomea Fusion, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

11/22/2023

Industry Report

Pages: 9

Critical Near-Term Data Catalysts In Our Universe Represent Thesis Definers

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Biomea Fusion, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

10/31/2023

Company Report

Pages: 11

3Q23 Results; Covalent Inhibitors Set Foot in Diverse Indications; T2D Updates in 4Q23

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Biomea Fusion, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

10/17/2023

Daily Note

Pages: 9

BMF-500 Begins Clinical Journey in Acute Leukemia; First Patient Dosed in COVALENT-103 Study

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Biomea Fusion, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

10/05/2023

Daily Note

Pages: 9

BMF-219 Stockpiling Diabetes Studies; Launch of Phase 2 COVALENT-112 in T1D Cleared by FDA

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Biomea Fusion, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

09/28/2023

Daily Note

Pages: 9

COVALENT-111 Gets Regulatory Green Light For Phase 2 Expansion Cohorts; Topline Dose Escalation Results Expected 4Q23

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party
// eof